Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian (PROFECTA-II)
An Open Label Randomized Active Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer
Sponsor: Laekna Limited
This PHASE2 trial investigates Platinum-resistant Ovarian Cancer and is currently completed. Laekna Limited leads this study, which shows 18 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
18 versions recorded-
Oct 2025 — Present [monthly]
Completed PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Completed PHASE2
-
Apr 2025 — Sep 2025 [monthly]
Completed PHASE2
-
Sep 2024 — Apr 2025 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 13 earlier versions
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Jan 2024 — Apr 2024 [monthly]
Active Not Recruiting PHASE2
-
Sep 2023 — Jan 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2023 — Sep 2023 [monthly]
Recruiting PHASE2
-
Sep 2022 — Jan 2023 [monthly]
Recruiting PHASE2
-
Jun 2022 — Sep 2022 [monthly]
Recruiting PHASE2
-
Jan 2022 — Jun 2022 [monthly]
Recruiting PHASE2
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE2
-
Apr 2021 — Dec 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Oct 2020 — Dec 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Laekna Limited
For direct contact, visit the study record on ClinicalTrials.gov .